In fact, Cabozantinib inhibits VEGFR and may modulate the microenvironment of HCC, reducing immunosuppression, recruiting cytotoxic T lymphocytes and enhancing response to ICIs. This evidence concerns the gene KDR and hepatocellular carcinoma.